| Gray-Zone Lymphoma studied in …STUDIED_INderived18 of 18show fewer |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03602157Phase 1 · active not recruiting Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03749018Phase 2 · active not recruiting Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · condition mapped ALIAS · 18 trials mapped (8 active) | — | — | Mediastinal Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07283822Phase 2 · recruiting Amping up With PemJAK · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · condition mapped ALIAS · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00001337Phase 2 · completed Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03255018Phase 2 · completed Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208853early Phase 1 · unknown An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01665768Phase 2 · completed Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04860674Phase 2 · unknown A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01943682Phase 1 · completed Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950220Phase 1 · completed Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ALIAS · 18 trials mapped (8 active) | — | — | Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03037177completed Mediastinal Grey Zone Lymphoma From the LYSA · condition mapped ALIAS · 18 trials mapped (8 active) | — | — | Mediastinal Gray-Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |